Profile of blonanserin for the treatment of schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 587-594

  Tenjin, Tomomi ^a   Miyamoto, Seiya ^a   Ninomiya, Yuriko ^a   Kitajima, Rei ^a   Ogino, Shin ^a   Miyake, Nobumi ^a   Yamaguchi, Noboru ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Blonanserin; Efficacy; Pharmacokinetics; Pharmacology; Safety; Schizophrenia

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ANTIFUNGAL AGENT; BARBITURIC ACID DERIVATIVE; BLONANSERIN; BROMOCRIPTINE; CARBAMAZEPINE; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 3A4; DILTIAZEM; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ERYTHROMYCIN; HALOPERIDOL; HISTAMINE H1 RECEPTOR; LEVODOPA; MUSCARINIC M1 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PHENYTOIN; PLACEBO; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; RIFAMPICIN; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 6 RECEPTOR; SULPIRIDE; UNINDEXED DRUG;

AKATHISIA; BINDING AFFINITY; COGNITION; CONSTIPATION; DIZZINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; JAPAN; MAINTENANCE THERAPY; MENSTRUATION; METABOLIC DISORDER; POSITIVE SYNDROME; PREFRONTAL CORTEX; QT PROLONGATION; REPEATED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; THIRST; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 84877037499     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S34433     Document Type: Review

References (45)

1. Insel TR. Rethinking schizophrenia. Nature. 2010;468(7321):187-193.
2. Miyamoto S, Duncan GE, Goff DC, Lieberman JA. Therapeutics of Schizophrenia. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia: Lippincott Williams & Wilkins; 2002:775-807.
3. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17(12):1206-1227.
4. Miyamoto S, Fleischhacker WW, Lieberman JA. Pharmacologic treatment of schizophrenia. In: Lieberman JA, Murray RM, editors. Comprehensive Care of Schizophrenia (Second Edition): A Textbook of Clinical Management. New York: Oxford University Press; 2012:77-138.
5. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of secondvs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10): 1079-1087.
6. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097.
7. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
8. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
9. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93.
10. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318-378.
11. Lehman AF, Lieberman JA, Dixon LB, et al. Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd ed. Am J Psychiatry. 2004;161(Suppl 2):1-56.
12. Miyake N, Miyamoto S, Jarskog LF. New serotonin/dopamine antagonists for the treatment of schizophrenia: are we making real progress? Clin Schizophr Relat Psychoses. 2012;6(3):122-133.
13. Kishi T, Matsuda Y, Nakamura H, Iwata N. Blonanserin for schizophrenia: Systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatr Res. 2013;47(2):149-154.
14. Une T, Kurumiya S. Pharmacological profile of blonanserin. Jpn J Clin Psychopharmacol. 2007;10(7):1263-1272.
15. Murasaki M. Preclinical and clinical features of blonanserin. Jpn J Clin Psychopharmacol. 2008;11(5):855-868.
16. Deeks ED, Keating GM. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs. 2010;24(1):65-84.
17. Oka M, Noda Y, Ochi Y, et al. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther. 1993;264(1):158-165.
18. Murasaki M, Nishikawa H, Ishibashi T. Dopamine-serotonin antagonist: Receptor binding profile of a novel antipsychotic blonanserin. Jpn J Clin Psychopharmacol. 2008;11(5):845-854.
19. Ohoyama K, Yamamura S, Hamaguchi T, et al. Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur J Pharmacol. 2011;653(1-3):47-57.
20. Lonasen® (blonanserin) [interview form]. Osaka, Japan: Dainippon Sumitomo Pharma Co, Ltd; 2012.
21. Suzuki H, Gen K. The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D2 and anti-serotonin 5-HT2A activity. Hum Psychopharmacol. 2010;25(4):342-346.
22. Inoue T, Osada K, Tagawa M, et al. Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(1):156-162.
23. Arakawa R, Okumura M, Ito H, et al. Positron emission tomography measurement of dopamine D(2) receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry. 2010;71(9):1131-1137.
24. Tateno A. PET evaluation for dopamine D2 receptor occupancy of blonanserin in schizophrenia patients. Jpn J Clin Psychopharmacol. 2011;14(2):334-341.
25. Saruwatari J, Yasui-Furukori N, Inoue Y, Kaneko S. Effect of dose timing in relation to food intake on systemic exposure to blonanserin. Eur J Clin Pharmacol. 2010;66(9):899-902.
26. Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs. 2009;23(7):615-625.
27. Murasaki M. Clinical evaluation of blonanserin for schizophrenia: a randomized controlled study comparing blonanserin with haloperidol. Jpn J Clin Psychopharmacol. 2007;10(11):2059-2079.
28. Miura S. Clinical evaluation of blonanserin for schizophrenia: a randomized controlled study comparing blonanserin with risperidone. Jpn J Clin Psychopharmacol. 2008;11(2):297-314.
29. Yang J, Bahk WM, Cho HS, et al. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. Clin Neuropharmacol. 2010;33(4):169-175.
30. Murasaki M. Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to determine safety and effectiveness in schizophrenic patients (Kanagawa Region Clinical Psychopharmacology Study Group). Jpn J Clin Psychopharmacol. 2007;10(12):2241-2257.
31. Kinoshita T. Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to determine safety and effectiveness in schizophrenic patients (Japan-wide study). Jpn J Clin Psychopharmacol. 2008;11(1):135-153.
32. Osada K, Miyamoto S, Maruta S, Miyake N, Nakano M, Yamaguchi N. Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to assess the safety and efficacy in patients with schizophrenia (Continuation of two long-term studies by request from patients). Jpn J Clin Psychopharmacol. 2009;12(11):2337-2351.
33. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull. 2000;26(1):119-136.
34. Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatr Clin North Am. 1993;16(2):295-312.
35. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology. 2009;23(3):315-336.
36. Bozikas VP, Andreou C. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. Aust N Z J Psychiatry. 2011;45(2):93-108.
37. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000;157(4):549-559.
38. Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry. 1994;51(2):124-131.
39. Wolwer W, Brinkmeyer J, Riesbeck M, et al. Neuropsychological impairments predict the clinical course in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2008;258 Suppl 5:28-34.
40. Matsui M, Sumiyoshi T, Arai H, Higuchi Y, Kurachi M. Cognitive functioning related to quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(1):280-287.
41. Miyake N, Miyamoto S, Takeuchi A, et al. Effect of new-generation antipsychotic blonanserin on cognitive impairment in schizophrenia: A randomized double-blind comparison with risperidone. Jpn J Clin Psychopharmacol. 2008;11(2):315-326.
42. Tenjin T, Miyamoto S, Miyake N, et al. Effect of blonanserin on cognitive function in antipsychotic-naive first-episode schizophrenia. Hum Psychopharmacol. 2012;27(1):90-100.
43. Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T. Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry Clin Neurosci. 2007;61(6):602-609.
44. Kaneda Y, Imakura A, Fujii A, Ohmori T. Schizophrenia Quality of Life Scale: validation of the Japanese version. Psychiatry Res. 2002; 113(1-2):107-113.
45. Miyamoto S, Merrill DB, Lieberman JA, Fleischhacker WW, Marder SR. Antipsychotic Drugs. In: Tasman A, Kay J, Lieberman JA, First MB, Maj M, editors. Psychiatry, 3rd ed. Chichester: John Wiley & Sons; 2008:2161-2201.